Niagen Bioscience (NAGE) Q4 2018 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2018 earnings summary
19 Nov, 2026Executive summary
FY 2018 net sales rose 49% YoY to $31.6M; TRU NIAGEN sales grew 238% to $18.5M, supporting the shift toward a consumer-focused business.
Q4 net sales increased 20% YoY to $9.1M; TRU NIAGEN sales reached $6.5M, up 143% YoY and 24% QoQ.
Financial highlights
Q4 gross margin was 52%, up 110 bps YoY; FY gross margin was 52%, up 150 bps YoY.
Q4 operating loss improved to $8.2M from $8.8M YoY; net loss was $8.2M versus $8.8M, and EPS was $(0.15) versus $(0.17).
FY operating loss from continuing operations was $33.2M versus $16.4M; net loss was $33.3M versus $11.4M.
Adjusted EBITDA was $(6.0)M in Q4 and $(26.0)M for FY 2018, versus $(5.2)M and $(11.2)M, respectively, in prior-year comparisons.
Outlook and guidance
2019 outlook calls for continued sales growth, continued gross-margin improvement, and selling, marketing and advertising expense roughly flat in absolute dollars and lower as a share of sales.
Cash-flow break-even remained targeted by Q4 2019 or early 2020, supported by higher sales and gross margins, improved marketing efficiency, and leverage of fixed overhead.
General and administrative expense was expected to be roughly flat in absolute dollars; legal costs were primarily driven by investments to protect intellectual property.
Latest events from Niagen Bioscience
- TRU NIAGEN drove 47% FY sales growth as margins improved and global expansion continued.NAGE
Q4 2019 - Q4 growth and stronger margins advanced the path toward break-even.NAGE
Q4 2020 - Consumer expansion and rare-disease development anchor a four-part growth strategy.NAGE
A.G.P. Virtual Consumer Showcase - A profitable NAD+ platform is funding expansion into IVs, skincare, and therapeutics.NAGE
Corporate presentation - Q3 sales fell 20% as investment and new launches targeted future growth.NAGE
Q3 2026 - Rare-disease drug ambitions extend a profitable NAD platform into new channels.NAGE
LD Micro 20th Annual Main Event Conference - Strong growth, innovation, and a leading NAD drug pipeline position the company for future success.NAGE
17th Annual Midwest IDEAS Conference - Strong NAD+ supplement sales, new skincare launches, and robust cash flow support biotech growth.NAGE
Canaccord Genuity's 46th Annual Growth Conference - Q2 2026 delivered $29.8M sales, $1M net income, and major telehealth and pharma launches.NAGE
Q2 2026